Related Experiment Video

Updated: Mar 25, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

10.1K

p53 family interactions and yeast: together in anticancer therapy

Sara Gomes1, Mariana Leão1, Liliana Raimundo1

  • 1UCIBIO/REQUIMTE, Laboratório de Microbiologia, Departamento de Ciências Biológicas, Faculdade de Farmácia, Universidade do Porto, Rua de Jorge Viterbo Ferreira n.° 228, 4050-313 Porto, Portugal.

Drug Discovery Today
|February 20, 2016
PubMed

Insights

Targeting p53 family protein-protein interactions (PPIs) with MDM2, MDMX, and mutant p53 offers promising cancer therapy strategies. Advances in understanding these interactions and yeast-based assays are accelerating anticancer drug development.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • The p53 protein family is a critical regulator of cellular responses to stress and a key target in cancer therapy.
  • Interactions between p53 family proteins, murine double minute (MDM)2, MDMX, and mutant p53 are complex and crucial for cancer development.
  • Targeting these specific protein-protein interactions (PPIs) presents a promising avenue for novel cancer treatments.

Purpose of the Study:

  • To summarize recent advancements in the biology of p53 family protein-protein interactions (PPIs).
  • To review the latest pharmacological developments targeting these PPIs for cancer therapy.
  • To highlight the role of yeast-based assays in advancing this research area.

Main Methods:

  • Literature review of recent studies on p53 family protein-protein interactions.
  • Analysis of pharmacological strategies targeting these interactions.
  • Examination of the utility of yeast-based assays in studying these PPIs.

Main Results:

  • Significant progress has been made in understanding the intricate PPIs involving p53 family proteins, MDM2, MDMX, and mutant p53.
  • Several pharmacological approaches targeting these PPIs have shown promise in preclinical studies.
  • Yeast-based assays have proven valuable in dissecting these complex interactions and screening for therapeutic modulators.

Conclusions:

  • Inhibition of p53 family PPIs represents a viable and advancing strategy for anticancer drug development.
  • Further research into these interactions and continued development of targeting agents are expected to yield new cancer therapies.
  • The integration of yeast-based assays accelerates the discovery and development of drugs targeting p53 family PPIs.

More Related Videos

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence04:56

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence

Published on: December 30, 2025

316
Purification of Ubiquitinated p53 Proteins from Mammalian Cells10:55

Purification of Ubiquitinated p53 Proteins from Mammalian Cells

Published on: March 21, 2022

2.9K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
38.9K
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
3.3K
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
10.4K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K